[1] Chen K, Song F, Calin GA, et al. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology [J]. Carcinogenesis, 2008, 29(7): 1301-1311. [2] Zhang D, Ni Z, Xu X, et al. miR-32 functions as a tumor suppressor and directly targets EZH2 in human oral squamous cell carcinoma [J]. Med Sci Monit, 2014, 20: 2527-2535. [3] Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisatin and revised mapping in 7q35 within the critical region for malignant myeloid disorders [J]. Eur J Hum Genet, 2000, 8(3): 174-180. [4] Chen H, Rossier C, Antonarakis SE, et al. Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2 [J]. Genomics, 1996, 38(1): 30-37. [5] Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer [J]. Nat Genet, 2010, 42(2): 100-110. Lee ST, Li Z, Wu Z, et al. Context-specific regulation of NF-κB tartet gene expression by EZH2 in breast cancers [J]. Mol Cell, 2011, 43(5): 798-810. [6] Yonemitsu Y, Imazeki F, Chinba T, et al. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma [J]. Hum Pathol, 2009, 40(9): 1304-1311. [7] Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3 [J]. Curr Opin Genet Dev, 2004, 14(2): 155-164. [8] Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J]. EMBO J, 2003, 22(20): 5323-5335. [9] Castagnino P, Kothapalli D, Hawthorne EA, et al. miR-221/miR-222 compensates for Skp2-mediated p27 degradation and is a primary target of cell cycle regulation by prostacyclin and cAMP [J]. PLoS One, 2013, 8(2): e56140. [10] Lin SC, Liu CJ, Lin JA, et al. miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis [J].Oral Oncol, 2010, 46(3): 204-208. [11] Uesugi A, Kozaki K, Tsurute T, et al. The tumor suppressive microrna miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer [J].Cancer Res, 2011, 71(17): 5765-5778. [12] Zhu D, Chen H, Yang X, et al. miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cance [J]. Once Targets Ther, 2015, 8: 1773-1783. [13] Yan SY, Chen MM, Li GM, et al. MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN [J]. Tumour Biol, 2015, 36(6): 4747-4755. [14] Yang J, Jiang H, Wang C, et al. Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects [J]. Biomed Pharmacother, 2015, 72(12):125-134. [15] Xu JQ, Zhang WB, Wang R, et al. MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9 [J]. Tumour Biol, 2014, 35(10): 9847-9853. [16] Yan C, Yu J, Liu Y, et al. MiR-32 promotes gastric carcinoma tumorigenesis by targeting Kruppel-like factor 4 [J]. Biochem Biophys Res Commun, 2015, 467(4): 913-920. [17] Xia H, Long J, Zhang R, et al. MiR-32 contributed to cell proliferation of human breast cancer cells by suppressing of PHLPP2 expression [J]. Biomed Pharmacother, 2015, 75: 105-110. |